

# Gibson Dunn Advises Apogee Therapeutics on \$402.5 Million Offering of Common Stock

Firm News | March 26, 2026

---

Gibson Dunn represented Apogee Therapeutics, Inc. in a public offering of common stock that generated aggregate gross proceeds of approximately \$402.5 million to Apogee.

Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with the potential for differentiated efficacy and dosing in the largest I&I markets, including for the treatment of Atopic Dermatitis (AD), asthma, Eosinophilic Esophagitis (EoE), Chronic Obstructive Pulmonary Disease (COPD) and other I&I indications.

Gibson Dunn regularly advises clinical-stage biotechnology companies on capital markets transactions in the life sciences sector.

The Gibson Dunn team included Ryan Murr, Branden Berns, Melanie Neary, Candice Johnson, Jasmine Vitug, and Anika Gidwani.

## Related People

[Ryan A. Murr](#)

[Branden C. Berns](#)

[Melanie E. Neary](#)

[Candice D. Johnson](#)

[Jasmine L. Vitug](#)

[Anika Gidwani](#)

## Related Capabilities

[Capital Markets](#)

[Life Sciences](#)